PCM
CBIO

Prelude Capital Management’s Crescent Biopharma CBIO Stock Holding History

Prelude Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-201
Closed -$239K – 1898
2019
Q2 		$239K Buy
201
+25
+14% +$29.9K 0.02% 680
2019
Q1 		$219K Buy
176
+174
+8,700% +$199K 0.02% 687
2018
Q4 		$2K Sell
2
-3
-60% -$3.61K ﹤0.01% 1685
2018
Q3 		$8K Buy
5
+2
+67% +$3.02K ﹤0.01% 1523
2018
Q2 		$5K Buy
+3
New +$5.16K ﹤0.01% 1556

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $718M AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return